A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

NCT02620306 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

351

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease

Interventions

DRUG: Fimsartan 60mg~120mg
DRUG: Fimsartan 60mg~120mg
DRUG: Losartan 50mg~100mg
DRUG: Losartan 50mg~100mg

Sponsor

Boryung Pharmaceutical Co., Ltd